{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T01:47:25Z","timestamp":1792547245138,"version":"4.5.0"},"reference-count":41,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,1,3]],"date-time":"2022-01-03T00:00:00Z","timestamp":1641168000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Microbiol."],"abstract":"<jats:p><jats:italic>Cryptosporidium parvum<\/jats:italic> is a highly prevalent protozoan parasite that causes a diarrheal disease in humans and animals worldwide. Thus far, the moderately effective nitazoxanide is the only drug approved by the United States Food and Drug Administration for treating cryptosporidiosis in immunocompetent humans. However, no effective drug exists for the severe disease seen in young children, immunocompromised individuals and neonatal livestock. <jats:italic>C. parvum<\/jats:italic> lacks the Krebs cycle and the oxidative phosphorylation steps, making it dependent solely on glycolysis for metabolic energy production. Within its glycolytic pathway, <jats:italic>C. parvum<\/jats:italic> possesses two unique enzymes, the bacterial-type lactate dehydrogenase (CpLDH) and the plant-like pyruvate kinase (CpPyK), that catalyze two sequential steps for generation of essential metabolic energy. We have previously reported that inhibitors of CpLDH are effective against <jats:italic>C. parvum<\/jats:italic>, both <jats:italic>in vitro<\/jats:italic> and <jats:italic>in vivo<\/jats:italic>. Herein, we developed an <jats:italic>in vitro<\/jats:italic> assay for the enzymatic activity of recombinant CpPyK protein and used it to screen a chemical compound library for inhibitors of CpPyK\u2019s activity. The identified inhibitors were tested (at non-toxic concentrations) for efficacy against <jats:italic>C. parvum<\/jats:italic> using <jats:italic>in vitro<\/jats:italic> assays, and an <jats:italic>in vivo<\/jats:italic> mouse infection model. We identified six CpPyK inhibitors that blocked <jats:italic>in vitro<\/jats:italic> growth and proliferation of <jats:italic>C. parvum<\/jats:italic> at low micromolar concentrations (EC<jats:sub>50<\/jats:sub> values ranging from 10.29 to 86.01 \u03bcM) that were non-toxic to host cells. Among those six compounds, two (NSC252172 and NSC234945) were found to be highly efficacious against cryptosporidiosis in immunocompromised mice at a dose of 10 mg\/kg body weight, with very significant reduction in parasite load and amelioration of intestinal pathologies. Together, these findings have unveiled inhibitors for an essential molecular target in <jats:italic>C. parvum<\/jats:italic> and demonstrated their efficacy against the parasite <jats:italic>in vitro<\/jats:italic> and <jats:italic>in vivo<\/jats:italic>. These inhibitors are, therefore, potential lead-compounds for developing efficacious treatments for cryptosporidiosis.<\/jats:p>","DOI":"10.3389\/fmicb.2021.800293","type":"journal-article","created":{"date-parts":[[2022,1,3]],"date-time":"2022-01-03T06:36:31Z","timestamp":1641191791000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":17,"title":["Cryptosporidium parvum Pyruvate Kinase Inhibitors With in vivo Anti-cryptosporidial Efficacy"],"prefix":"10.3389","volume":"12","author":[{"given":"Shahbaz M.","family":"Khan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuejin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William H.","family":"Witola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,1,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1126\/science.1094786","article-title":"Complete genome sequence of the apicomplexan, Cryptosporidium parvum.","volume":"304","author":"Abrahamsen","year":"2004","journal-title":"Science"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/J.EJMECH.2020.112652","article-title":"An insight on medicinal attributes of 1,2,4-triazoles.","volume":"205","author":"Aggarwal","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"B3","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1016\/J.EJMECH.2018.03.076","article-title":"An overview of quinazolines: pharmacological significance and recent developments.","volume":"151","author":"Alagarsamy","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"B4","doi-asserted-by":"publisher","first-page":"314","DOI":"10.2307\/3282084","article-title":"Isolation of Cryptosporidium oocysts and sporozoites using discontinuous sucrose and isopycnic Percoll gradients.","volume":"73","author":"Arrowood","year":"1987","journal-title":"J. Parasitol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1016\/0006-291X(91)91647-U","article-title":"Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells.","volume":"175","author":"Artursson","year":"1991","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"B6","article-title":"The glycolytic pathway is tightly controlled","author":"Berg","year":"2002","journal-title":"Biochemistry"},{"key":"B7","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1111\/tid.12336","article-title":"Cryptosporidium infection after renal transplantation in an endemic area.","volume":"17","author":"Bhadauria","year":"2015","journal-title":"Transpl. Infect. Dis."},{"key":"B8","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/S1473-3099(14)70772-8","article-title":"A review of the global burden, novel diagnostics, therapeutics, and vaccine targets for cryptosporidium.","volume":"15","author":"Checkley","year":"2015","journal-title":"Lancet Infect. Dis."},{"key":"B9","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.vetmic.2013.07.001","article-title":"Case-control study of microbiological etiology associated with calf diarrhea.","volume":"166","author":"Cho","year":"2013","journal-title":"Vet. Microbiol."},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0046875","article-title":"Crystal structure of Cryptosporidium parvum pyruvate kinase.","volume":"7","author":"Cook","year":"2012","journal-title":"PLoS One"},{"key":"B11","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1201\/9781351071260-2","article-title":"Techniques and laboratory maintenance of cryptosporidium","author":"Current","year":"2018","journal-title":"Cryptosporidiosis of Man and Animals"},{"key":"B12","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1097\/MOG.0000000000000016","article-title":"Gastrointestinal infections after transplantation.","volume":"30","author":"Danziger-Isakov","year":"2014","journal-title":"Curr. Opin. Gastroenterol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/0166-6851(95)02527-8","article-title":"Comparison of the phosphofructokinase and pyruvate kinase activities of Cryptosporidium parvum, Eimeria tenella and Toxoplasma gondii.","volume":"76","author":"Denton","year":"1996","journal-title":"Mol. Biochem. Parasitol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.ijpddr.2018.01.003","article-title":"Discovery of ebselen as an inhibitor of Cryptosporidium parvum glucose-6-phosphate isomerase (CpGPI) by high-throughput screening of existing drugs.","volume":"8","author":"Eltahan","year":"2018","journal-title":"Int. J. Parasitol. Drugs Drug Resist."},{"key":"B15","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1111\/jeu.12690","article-title":"The action of the hexokinase inhibitor 2-deoxy-d-glucose on Cryptosporidium parvum and the discovery of activities against the parasite hexokinase from marketed drugs.","volume":"66","author":"Eltahan","year":"2019","journal-title":"J. Eukaryot. Microbiol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1111\/j.1574-6968.1997.tb10393.x","article-title":"Glycolytic enzyme activities in Cryptosporidium parvum oocysts.","volume":"151","author":"Entrala","year":"1997","journal-title":"FEMS Microbiol. Lett."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1016\/S0020-7519(00)00135-1","article-title":"Epidemiology of cryptosporidium: transmission, detection and identification.","volume":"30","author":"Fayer","year":"2000","journal-title":"Int. J. Parasitol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/0079-6107(93)90001-Z","article-title":"Evolution of glycolysis.","volume":"59","author":"Fothergill-Gilmore","year":"1993","journal-title":"Prog. Biophys. Mol. Biol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"2503","DOI":"10.1128\/JCM.36.9.2503-2508.1998","article-title":"The gamma interferon gene knockout mouse: a highly sensitive model for evaluation of therapeutic agents against Cryptosporidium parvum.","volume":"36","author":"Griffiths","year":"1998","journal-title":"J. Clin. Microbiol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.chom.2020.09.007","article-title":"The biology of the intestinal intracellular parasite cryptosporidium.","volume":"28","author":"Gu\u00e9rin","year":"2020","journal-title":"Cell Host Microbe"},{"key":"B21","first-page":"315","article-title":"An \u201cin vitro selectivity index\u201d for evaluation of cytotoxicity of antitrypanosomal compounds.","volume":"9","author":"Kaminsky","year":"1996","journal-title":"In Vitro Toxicol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/S0140-6736(13)60844-2","article-title":"Burden and aetiology of diarrhoeal disease in infants and young children in developing countries (the Global Enteric Multicenter Study, GEMS): a prospective, case-control study.","volume":"382","author":"Kotloff","year":"2013","journal-title":"Lancet"},{"key":"B23","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1128\/AAC.01915-15","article-title":"Inhibition of calcium-dependent protein kinase 1 (CDPK1) in vitro by pyrazolopyrimidine derivatives does not correlate with sensitivity of Cryptosporidium parvum growth in cell culture.","volume":"60","author":"Kuhlenschmidt","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1007953","article-title":"Novel lactate dehydrogenase inhibitors with in vivo efficacy against Cryptosporidium parvum.","volume":"15","author":"Li","year":"2019","journal-title":"PLoS Pathog."},{"key":"B25","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/S0169-409X(00)00129-0","article-title":"Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings.","volume":"46","author":"Lipinski","year":"2001","journal-title":"Adv. Drug Deliv. Rev."},{"key":"B26","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1002\/MED.21391","article-title":"Anthraquinones as pharmacological tools and drugs.","volume":"36","author":"Malik","year":"2016","journal-title":"Med. Res. Rev."},{"key":"B27","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1093\/INFDIS\/165.4.772","article-title":"Paromomycin inhibits cryptosporidium infection of a human enterocyte cell line.","volume":"165","author":"Marshall","year":"1992","journal-title":"J. Infect. Dis."},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1093\/INFDIS\/JIAB434","article-title":"Pathogens associated with linear growth faltering in children with diarrhea and impact of antibiotic treatment: the global enteric multicenter study.","author":"Nasrin","year":"2021","journal-title":"J. Infect. Dis."},{"key":"B29","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1093\/clinids\/6.3.313","article-title":"Cryptosporidiosis: clinical, epidemiologic, and parasitologic review.","volume":"6","author":"Navin","year":"1984","journal-title":"Rev. Infect. Dis."},{"key":"B30","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1097\/QAD.0b013e3283437e88","article-title":"Cryptosporidiosis in patients with HIV\/AIDS.","volume":"25","author":"O\u2019Connor","year":"2011","journal-title":"AIDS"},{"key":"B31","doi-asserted-by":"crossref","DOI":"10.4269\/ajtmh.2007.76.938","article-title":"Detection and quantification of Cryptosporidium in HCT-8 cells and human fecal specimens using real-time polymerase chain reaction.","volume":"76","author":"Parr","year":"2007","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1017\/S0031182014001085","article-title":"Cryptosporidium species in humans and animals: current understanding and research needs.","volume":"141","author":"Ryan","year":"2014","journal-title":"Parasitology"},{"key":"B33","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.cvfa.2019.11.005","article-title":"Cryptosporidium and giardia in ruminants.","volume":"36","author":"Santin","year":"2020","journal-title":"Vet. Clin. North Am. Food Anim. Pract."},{"key":"B34","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.ijpara.2020.03.002","article-title":"Long-term production effects of clinical cryptosporidiosis in neonatal calves.","volume":"50","author":"Shaw","year":"2020","journal-title":"Int. J. Parasitol."},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1186\/s13567-017-0447-0","article-title":"Bovine cryptosporidiosis: impact, host-parasite interaction and control strategies.","volume":"48","author":"Thomson","year":"2017","journal-title":"Vet. Res."},{"key":"B36","doi-asserted-by":"publisher","first-page":"2615","DOI":"10.1021\/JM020017N","article-title":"Molecular properties that influence the oral bioavailability of drug candidates.","volume":"45","author":"Veber","year":"2002","journal-title":"J. Med. Chem."},{"key":"B37","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/J.CBPA.2010.02.018","article-title":"Privileged scaffolds for library design and drug discovery.","volume":"14","author":"Welsch","year":"2010","journal-title":"Curr. Opin. Chem. Biol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1016\/j.ijpara.2017.05.002","article-title":"Targeted gene knockdown validates the essential role of lactate dehydrogenase in Cryptosporidium parvum.","volume":"47","author":"Witola","year":"2017","journal-title":"Int. J. Parasitol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1016\/j.rvsc.2020.08.002","article-title":"Cryptosporidium \u2013 an update with an emphasis on foodborne and waterborne transmission.","volume":"132","author":"Zahedi","year":"2020","journal-title":"Res. Vet. Sci."},{"key":"B40","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/j.ijpara.2018.01.005","article-title":"Morpholino-mediated in vivo silencing of Cryptosporidium parvum lactate dehydrogenase decreases oocyst shedding and infectivity.","volume":"48","author":"Zhang","year":"2018","journal-title":"Int. J. Parasitol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1201\/9781420052275-3","article-title":"Biochemistry","author":"Zhu","year":"2007","journal-title":"Cryptosporidium and Cryptosporidiosis"}],"container-title":["Frontiers in Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmicb.2021.800293\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,3]],"date-time":"2022-01-03T06:36:36Z","timestamp":1641191796000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmicb.2021.800293\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,3]]},"references-count":41,"alternative-id":["10.3389\/fmicb.2021.800293"],"URL":"https:\/\/doi.org\/10.3389\/fmicb.2021.800293","relation":{},"ISSN":["1664-302X"],"issn-type":[{"value":"1664-302X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,3]]},"article-number":"800293"}}